Yan Leyfman: New Hope in Irinotecan-Refractory Metastatic Colorectal Cancer
Yan Leyfman, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn about a paper by Scott Kopetz et al. published in Nature Medicine:
“New Hope in mCRC:
At PROCEADECRC01 Phase 1 trial, Precem-TcT (anti-CEACAM5 ADC with exatecan payload) shows promising activity in irinotecan-refractory metastatic colorectal cancer.
Key Highlights:
- Targets CEACAM5, overexpressed in CRC
- Confirmed PRs in 7.5% (15% unconfirmed); all at ≥2.4 mg/kg
- Median PFS: 6.7 months at ≥2.4 mg/kg
- Favorable safety profile: No ILD or ocular toxicity
- Stable linker–payload confirmed by PK data
- Ongoing dose optimization at 2.4 and 2.8 mg/kg Q3W
Early signals support Precem-TcT as a potential option for heavily pretreated mCRC.”
Title: Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial
Authors: Scott Kopetz, Valentina Boni, Ken Kato, Kanwal P. S. Raghav, Maria Vieito, Athanasios Pallis, Christina Habermehl, Abdul Siddiqui, Perrine Courlet, Willem Sloot, Sabine Raab-Westphal, Felix Hart & Ildefonso Rodriguez-Rivera
You can read the Full Article in Nature Medicine.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023